Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
6.00
-0.24 (-3.85%)
At close: Jul 13, 2026, 4:00 PM EDT
6.01
+0.01 (0.17%)
Pre-market: Jul 14, 2026, 7:28 AM EDT
Vanda Pharmaceuticals Market Cap
Vanda Pharmaceuticals has a market cap or net worth of $360.81 million as of July 14, 2026. Its market cap has increased by 27.00% in one year.
Market Cap
360.81M
Enterprise Value
171.58M
1-Year Change
27.00%
Ranking
Category
Stock Price
$6.00
Market Cap Chart
Since April 12, 2006, Vanda Pharmaceuticals's market cap has increased from $209.50M to $360.81M, an increase of 72.23%. That is a compound annual growth rate of 2.72%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 13, 2026 | 360.80M | -30.78% |
| Dec 31, 2025 | 521.20M | 86.61% |
| Dec 31, 2024 | 279.30M | 15.03% |
| Dec 29, 2023 | 242.80M | -41.94% |
| Dec 30, 2022 | 418.20M | -52.16% |
| Dec 31, 2021 | 874.10M | 21.64% |
| Dec 31, 2020 | 718.60M | -17.90% |
| Dec 31, 2019 | 875.30M | -36.13% |
| Dec 31, 2018 | 1.37B | 100.69% |
| Dec 29, 2017 | 682.90M | -2.57% |
| Dec 30, 2016 | 700.90M | 75.84% |
| Dec 31, 2015 | 398.60M | -17.90% |
| Dec 31, 2014 | 485.50M | 17.87% |
| Dec 31, 2013 | 411.90M | 294.54% |
| Dec 31, 2012 | 104.40M | -21.97% |
| Dec 30, 2011 | 133.80M | -49.57% |
| Dec 31, 2010 | 265.30M | -13.30% |
| Dec 31, 2009 | 306.00M | 2,200.75% |
| Dec 31, 2008 | 13.30M | -92.75% |
| Dec 31, 2007 | 183.40M | -66.04% |
| Dec 29, 2006 | 540.00M | 157.76% |
| Apr 12, 2006 | 209.50M | - |
View and export this data all the way back to 2006. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Larimar Therapeutics | 388.83M |
| X4 Pharmaceuticals | 381.99M |
| Atea Pharmaceuticals | 379.33M |
| Fennec Pharmaceuticals | 373.42M |
| Adlai Nortye | 369.60M |
| Lexeo Therapeutics | 364.73M |
| Q32 Bio | 362.53M |
| Vicore Pharma Holding AB | 355.32M |